VEGFA and neoplasm: Benserazide, an inhibitor of CBS, in combination with paclitaxel, decreased SIRT1 sulfhydration and hypoxia-inducible factor 1-alpha/vascular endothelial growth factor (HIF-1α/VEGF) expression in tumor models [125].